SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs Q3 earnings report is the dominant focus, with traders watching managements outlook on subscriber engagement, growth and advertising amid a steep share-price decline. Views are split: bears fear continued weakness and content concerns, while bulls argue expectations are low and a solid outlook could support a rebound.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea is selling off amid trader concerns that its planned Sea Cloud launch and a potential Monee public listing could add uncertainty and spending pressure while Shopee faces subsidy competition from TikTok Shop and Temu. The community is divided over whether the decline is an overreaction to those plans or a sign of deeper competitive and profitability concerns.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SLS is drawing attention as traders anticipate the 80-event trigger for final analysis of SELLASs Phase 3 REGAL trial; the last disclosed count cited in the discussion was 78. CEO Angelos Stergious anniversary message has also fueled unconfirmed buyout speculation, while skeptics stress that no trial update or deal is confirmed and attribute the rebound to trading and biotech-sector strength.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces earnings beat and raised outlook have been overshadowed by a sharp selloff, with traders pointing to rising costs, weaker cash conversion, and an insurance-business loss as concerns about profitability. The reaction has frustrated bullish holders, while others see the pullback as a buying opportunity and note that strong orders and demand remain intact.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Anticipation of Sareptas DM1 and FSHD siRNA data is driving discussion, with traders pointing to positive Arrowhead results and Sareptas preclinical DM1 findings as support for the platform. Others caution that optimism and suspected short covering are not substitutes for human readouts, and debate whether the share move reflects company-specific momentum or broader biotech strength.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads agreement to sell its prenatal testing business to Labcorp is driving a sharp rally, with traders viewing the cash proceeds as a way to strengthen the balance sheet and refocus on oncology. Others are cautious that the divestiture also removes a significant revenue stream from a company already facing business and profitability concerns.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings beat and new buyback were overshadowed by a narrowed full-year profit outlook with the midpoint unchanged, prompting a sharp selloff. Traders are divided between buying the dip on stronger cash-flow prospects and seeing the guidance as a reason for the stocks decline.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports attention is centered on Phase 2 results for RAP-219 in bipolar mania, which traders say met the primary and secondary endpoints and prompted bullish reactions and analyst upgrades. The response is divided: skeptics question the modest efficacy signal and point to agitation events and higher discontinuations, while shares have shown sharp volatility after the initial enthusiasm.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grummans strong third-quarter results, raised 2026 earnings outlook and record backlog are driving the move higher. Traders are broadly bullish on the earnings and defense-demand outlook, though some are watching whether the shares can hold their gains after the jump.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMPs sharp rally has sparked breakout and short-squeeze speculation, with traders pointing to bullish chart patterns and the tokens limited supply. Some see it as a catch-up move after prolonged underperformance, while others remain skeptical and want a clearer catalyst; the institutional push and planned V4 are cited as longer-term bullish context.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Artelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening?

Artelo Biosciences, Inc. (NASDAQ: ARTL) shares are surging Wednesday afternoon after the clinical-stage biopharmaceutical company announced the filing of a new provisional patent application covering its drug candidate ART27.13 for the treatment of obesity.read more...

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers

Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million.
Vistagen Therapeutics (NASDAQ:VTGN) sharesread more...

Traders Rush into AI, Biotech, and Emerging Tech

Momentum traders are aggressively rotating into AI infrastructure, biotech catalysts, blockchain exposure, and emerging technology plays as speculative appetite continues heating up across small-cap and high-growth sectors. $KBLB, $OTLK, $PHGE, $UZX, $QTEK $ARTL, $VCIG, $YMAT, $NCRA

What's Behind The Rise In Artelo Biosciences Stock?

Artelo Biosciences, Inc. (NASDAQ:ARTL) shares jumped on Monday after the company announced the publication of a peerreviewed article highlighting FABP5 as a therapeutic target for pain.read more...

Rogan’s Runners Market Ignites

The market is feeling the effect of Joe Rogan getting in President Trump’s ear and psychedelic therapeutics gaining regulatory tailwinds. Meanwhile, adjacent sectors are quietly building foundational breakthroughs. Wearables are evolving into neural interfaces, biomaterials are transitioning from lab curiosity to production reality, and oncology platforms continue their grind through clinical validation. $KBLB, $WLDS, $ARTL, $ENVB, $TOVX, $PBM, $CMND, $CMPS, $HELP,

Why Is ARTL Stock Soaring Today?

Equity

Artelo stated that the Nasdaq sent a letter confirming the company is in compliance with the exchange’s rule requiring a minimum of $2.5 million in stockholders’ equity and another rule requiring an annual shareholders’ meeting.

ARTL, BFRG, HKIT Among Stocks Soaring Before The Bell — Top Pre-Market Gainers Today

U.S. equities gained in Tuesday’s pre-market trade after President Donald Trump reportedly stated that the Iran war could be ended without a full reopening of the Strait of Hormuz.

Medical Stocks To Research - March 27th

UnitedHealth Group, Artelo Biosciences, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly...

Artelo Biosciences Stock Skyrockets 205%

(RTTNews) - Shares of Artelo Biosciences, Inc. (ARTL) are skyrocketing about 205 percent on Friday morning trading despite no corporate-related announcements to influence the movement...

AI, Biotech, and Biologics Drive Big Narratives

A new wave of healthcare innovation, powered by artificial intelligence, next-generation biologics, and shifting regulatory pathways, is colliding with market dynamics to create both breakthrough potential and high-volatility trading setups. $ARTL, $TGNT, $ADMA, $RCKT, $LTRN, $GCTK

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

Artelo Biosciences Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Artelo CEO Gregory D. Gorgas on Tuesday stated that the interim data in the Phase 2 trial of ART27.13 is encouraging.</li><li>Artelo added that ART27.13 is currently under investigation as an orally administered agent for the treatment of glaucoma in an externally funded Phase 2 study.</li><li>The company is also developing ART27.13 as a potential companion therapy to preserve muscle in patients undertaking GLP-1 treatment.</li></ul>Artelo Biosciences Inc. (ARTL) shares soared more than 21% in Tuesday’s pre-market trade&nbsp;before losing most of the gains to hover about 4% higher in the day’s opening trade after the company announced that it has regained compliance with Nasdaq’s listing requirements.Artelo stated that the Nasdaq sent a letter confirming the company is in compliance with the exchange’s rule requiring a minimum of $2.5 million in stockholders’ equity and another rule requiring an annual shareholders’ meeting.The company stated that, in accordance with Nasdaq’s listing rules, Artelo will be subject to a mandatory panel monitor for a period of one year from the date of this letter.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences</a> trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Artelo CEO Says ART27.13 Interim Data Is Encouraging</h2>Artelo CEO Gregory D. Gorgas stated on Tuesday that the interim data from the Phase 2 trial of ART27.13 is encouraging.“With this matter behind us, we remain focused on disciplined execution across our portfolio, including progressing potential partnership negotiations with ART27.13 boosted by the encouraging Phase 2 CAReS interim data suggesting its potential for mitigating or reversing the effects of cancer anorexia-cachexia syndrome,” he said.Artelo added that ART27.13 is currently under investigation as an orally administered agent for the treatment of glaucoma in an externally funded Phase 2 study.<h2 class="st-heading-2">Artelo Expands ART27.13’s Development</h2>The company announced last month that it had expanded development of ART27.13 as a potential companion therapy to preserve muscle in patients undergoing glucagon-like peptide-1 (GLP-1) receptor agonist therapy.Artelo cited observations among patients with cancer anorexia and cachexia showing improvements in lean body mass and physical activity during ART27.13’s Phase 2 trial.The company also closed an $11 million private placement of 3.2 million shares last week, which it intends to use toward the repayment of certain bridge debt and to meet other working capital requirements.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up 84% year-to-date, but down 58% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 35% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-fall-ongoing-us-strikes-iran-trump-tuesday-deadline/cZJJpRQRIpL">Dow Futures Fall Over 200 Points Amid Ongoing US Strikes Against Iran, While Trump’s Tuesday Deadline Draws Closer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Artelo Biosciences logo is seen displayed on a smartphone screen.

Vanguard Extended Market ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$2.70
Prev Close	$2.66
Open	$2.70
Dividend Yield	0.00%
50-Day Moving Average	$5.05
Beta	0.61
Avg. Volume	1.34M
PE Ratio	-0.01

52-Week High	$179.19
52-Week Low	$2.66
Market Capitalization	$1.46M
EPS (Annual)	-$337.93
Price to Book	0.25
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

ARTL Fundamentals